活检之争:组织活检与液体活检在肝细胞癌中的作用
综述探讨肝细胞癌诊疗中组织活检与液体活检各自的挑战与潜力。免疫联合治疗扩展了不可切除肝细胞癌的选择,分子检测用于早期发现与管理正在兴起。液体活检分析循环肿瘤细胞、DNA和细胞外囊泡,但敏感度、成本和可及性仍有挑战;多分析物液体活检面板早期结果有前景,全面临床验证仍在进行。
要点
- 液体活检分析循环肿瘤细胞、DNA和细胞外囊泡,是颇具前景的替代手段。
- 液体活检仍存在敏感度、成本与可及性相关挑战。
- 多分析物液体活检面板早期结果有前景,全面临床验证仍在进行。
核心结论
- 组织活检与液体活检方法不同,将共同重塑肝细胞癌管理的未来。
研究设计与样本
- 综述,探讨组织活检与液体活检在肝细胞癌中的挑战与潜力。
主要发现
- 免疫联合治疗使不可切除肝细胞癌患者的治疗选择显著扩展。
- 肝细胞癌早期检测仍面临超声敏感度、可及性和患者对监测依从性的问题。
- 缺乏可预测治疗反应的可靠生物标志物,限制了肝细胞癌的准确分层。
- 组织活检未在肝细胞癌中常规开展,分子诊断的潜力尚未被充分利用。
- 多分析物液体活检面板早期结果有前景,全面临床验证仍在进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 液体活检仍存在敏感度、成本与可及性相关挑战。
- 多分析物液体活检面板的全面临床验证仍在进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The diagnosis and management of hepatocellular carcinoma (HCC) have improved significantly in recent years. With the introduction of immunotherapy-based combination therapy, there has been a notable expansion in treatment options for patients with unresectable HCC. Simultaneously, innovative molecular tests for early detection and management of HCC are emerging. This progress prompts a key question: as liquid biopsy techniques rise in prominence, will they replace traditional tissue biopsies, or will both techniques remain relevant? Given the ongoing challenges of early HCC detection, including issues with ultrasound sensitivity, accessibility, and patient adherence to surveillance, the evolution of diagnostic techniques is more relevant than ever. Furthermore, the accurate stratification of HCC is limited by the absence of reliable biomarkers which can predict response to therapies. While the advantages of molecular diagnostics are evident, their potential has not yet been fully harnessed, largely because tissue biopsies are not routinely performed for HCC. Liquid biopsies, analysing components such as circulating tumour cells, DNA, and extracellular vesicles, provide a promising alternative, though they are still associated with challenges related to sensitivity, cost, and accessibility. The early results from multi-analyte liquid biopsy panels are promising and suggest they could play a transformative role in HCC detection and management; however, comprehensive clinical validation is still ongoing. In this review, we explore the challenges and potential of both tissue and liquid biopsy, highlighting that these diagnostic methods, while distinct in their approaches, are set to jointly reshape the future of HCC management.
引用
- Lehrich BM, Zhang J, Monga SP, et al. Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma. J Hepatol. 2023. PMID: 38104635. doi:10.1016/j.jhep.2023.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。